FMP
Enter
API Tools
Extras
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.3 USD
0.0412 (13.73%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
671.09k
10.37M
7.98M
4.06M
1.84M
-
-
-
-
-
Total Cash %
100
100
100
100
100
100
100
100
100
Receivables
-
-
-
-
-
-
-
-
-
-
Receivables %
100
100
100
100
100
100
100
100
100
Inventories
-
-
-
-
-
-
-
-
-
-
Inventories %
100
100
100
100
100
100
100
100
100
Payable
141.86k
278.96k
155.49k
113.8k
102.96k
-
-
-
-
-
Payable %
100
100
100
100
100
100
100
100
100
Cap Ex
-
-
-1.8k
-149.78k
-
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
